Ignite Creation Date:
2024-05-05 @ 6:55 PM
Last Modification Date:
2024-10-26 @ 9:38 AM
Study NCT ID:
NCT00560482
Status:
COMPLETED
Last Update Posted:
2015-10-26
First Post:
2007-11-15
Brief Title:
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Sponsor:
Active Biotech AB
Organization:
Active Biotech AB
Study Overview
Official Title:
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate ABR-215050 as a possible treatment for prostate cancer
Detailed Description:
For asymptomatic patients with Castrate-Resistant Prostate Cancer CRPC a window of opportunity is present During this window of opportunity an intervention with little or no toxicity and the potential for extending the symptom-free period would be of great value to keep metastatic patients in an asymptomatic stage and thus delay the introduction of chemotherapy The purpose of this study is to evaluate the safety and efficacy of ABR-215050 as an interventional agent for this role
Overall survival for patients participating in study 07TASQ08 will be evaluated retrospectively using a separate study protocol 11TASQ11
Overall survival for patients participating in study 07TASQ08 will be evaluated retrospectively using a separate study protocol 11TASQ11
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT No 2007-003470-26 | None | None | None |